Biotech

All Articles

Actinogen's cortisol blocker neglects phase 2 anxiety study

.Actinogen Medical's cortisol blocker has actually missed out on the major endpoint of a phase 2 res...

Bivictrix chooses going exclusive only technique to take ADC in to medical clinic

.Antibody-drug conjugates (ADCs) have gone to the center of several a billion-dollar biobuck licensi...

TPG bests up funds to $580M for financial investments all over lifestyle scientific researches

.Resource manager TPG, which has actually assisted biotechs including Sionna Therapies as well as Sa...

Merck stops period 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT course has endured another drawback. Months after shuttering a phase 3 most ...

After a tough year, Exscientia folds up into Recursion

.After a year defined by pipe cuts, the shift of its own chief executive officer and layoffs, Exscie...

Cullinan, after $25M bargain, return bispecific to Port

.Cullinan Therapy was actually impressed good enough along with Harbour BioMed's bispecific immune s...

A deeper examine Intense Biotech's Strong 15

.Within this week's episode of "The Top Line," our team are actually diving right into Strong Biotec...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's party celebrating the commendation of Alzheimer's dis...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of notable management hirings, firings and also ...

Lykos will inquire FDA to reevaluate its choice following being rejected of MDMA treatment for post-traumatic stress disorder

.Observing a bad presenting for Lykos Rehabs' MDMA applicant for post-traumatic stress disorder at a...